NASDAQ: CBIOCatalyst Biosciences Inc Stock
$0.21-0.01 (-4.55%)
Updated Jun 1, 2023
CBIO Price
$0.21
Fair Value Price
$0.90
Market Cap
$8.04M
52 Week Low
$0.19
52 Week High
$2.09
P/E
1.01x
P/B
-0.31x
P/S
N/A
PEG
N/A
Dividend Yield
0%
Revenue
$0.00
Earnings
$6.55M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.44
Operating Cash Flow
-$27M
Beta
1.18
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CBIO Overview
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CBIO scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CBIO ($0.21) is undervalued by 76.32% relative to our estimate of its Fair Value price of $0.90 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CBIO ($0.21) is significantly undervalued by 76.32% relative to our estimate of its Fair Value price of $0.90 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CBIO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 35 more CBIO due diligence checks available for Premium users.
Be the first to know about important CBIO news, forecast changes, insider trades & much more!
CBIO News
Valuation
CBIO fair value
Fair Value of CBIO stock based on Discounted Cash Flow (DCF)
Price
$0.21
Fair Value
$0.90
Undervalued by
76.65%
CBIO ($0.21) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CBIO ($0.21) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
1.01x
Industry
11.46x
Market
52.37x
CBIO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CBIO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.31x
Industry
5.14x
CBIO's financial health
Profit margin
Revenue
$0.0
Net Income
$260.0k
Profit Margin
0%
CBIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.8M
Liabilities
$11.4M
Debt to equity
-0.44
CBIO's short-term assets ($14.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CBIO's short-term assets ($14.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CBIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.2M
Investing
$411.0k
Financing
-$7.8M
CBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CBIO vs Biotech Stocks
Catalyst Biosciences Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.